Close search
Resources

Newsfeeds

Favorite Articles

    Tags

    Categories

    Authors

    18 results
    Date
    Kinetisol technology - scale-up approach

    KinetiSol® technology: scale-up approach

    Newsfeeds - 06/12/2024 -
    This presentation highlights Justin Keen, Senior Vice President of Operations at AustinPx, as he delves into KinetiSol technology—a groundbreaking method for creating amorphous solid dispersions. Discover how KinetiSol addresses the …
    Image improving active pharmaceutical ingredient formulation by hot melt extrusion

    Improving active pharmaceutical ingredient formulation by hot melt extrusion

    Newsfeeds - 10/06/2024 -
    This poster, presented at the PBP World Meeting 2024 in Vienna, explores the integration of AI and big data in pharmaceutical research, revolutionizing drug discovery. Despite advancements, challenges arise due …
    Image Rapid And Material-Sparing Feasibility Screening For Hot Melt Extrusion

    Rapid and material-sparing feasibility screening for hot melt extrusion

    Newsfeeds - 05/04/2024 -
    Amorphous solid dispersions (ASD) present a solution for enhancing the bioavailability of crystalline APIs that are otherwise poorly soluble. Two primary methods for manufacturing ASDs are spray drying and hot …
    The impact of diluents on the compaction, dissolution, and physical stability of amorphous solid dispersion tablets

    The impact of diluents on the compaction, dissolution, and physical stability of amorphous solid dispersion tablets

    Papers - 22/02/2024 - by Dongyue Yu, Stephen W. Hoag
    The amorphous solid dispersion (ASD) method proves effective in enhancing the solubility, dissolution, and bioavailability of poorly water-soluble medications. However, these forms are prone to transitioning into more thermodynamically stable, …
    Comprehensive evaluation of polymer types and ratios in Spray-Dried Dispersions: Compaction, Dissolution, and physical stability

    Comprehensive evaluation of polymer types and ratios in Spray-Dried Dispersions: compaction, dissolution, and physical stability

    Papers - 25/01/2024 - by Dongyue Yu, Haichen Nie, Stephen W. Hoag
    The amorphous solid dispersion (ASD) method is a well-established approach to enhance the solubility and bioavailability of poorly soluble drugs. Although a significant number of ASD products are in tablet …
    Effect of drug loading and relative humidity on the mechanical properties and tableting performance of Celecoxib–PVP/VA 64 amorphous solid dispersions

    Effect of drug loading and relative humidity on the mechanical properties and tableting performance of Celecoxib–PVP/VA 64 amorphous solid dispersions

    Papers - 25/09/2023 - by Frederick Osei-Yeboah, Changquan Calvin Sun
    The mechanical characteristics of amorphous solid dispersions (ASDs) based on polymers are susceptible to alterations in relative humidity (RH) conditions. This study aims to elucidate the influence of RH on …
    Downstream processing of amorphous solid dispersions into orodispersible tablets

    Downstream processing of amorphous solid dispersions into orodispersible tablets

    Papers - 25/01/2023 - by Marcel Kokott, Stefan Klinken, Jörg Breitkreutz, Raphael Wiedey
    The development of patient-friendly oral solid dosage forms for amorphous solid dispersions (ASDs) remains a challenging task. Orodispersible tablets (ODTs) present a promising alternative to enhance patient compliance. Two distinct …
    tablet white powder

    Formulation development and compaction of itraconazole amorphous solid dispersions tablets using quality by design principles

    Bulletins - 02/01/2023 - by Hetvi Triboandas, Mariana Bezerra, Walkiria Schlindwein
    Itraconazole (ITZ), a BCS Class II drug exhibiting low solubility (1-4 ng/mL in water) requires formulation enhancement to achieve enhanced bioavailability. To tackle this problem amorphous solid dispersions (ASDS) of …
    Itraconazole Amorphous Solid Dispersion Tablets: Formulation and Compaction Process Optimization Using Quality by Design Principles and Tools

    Itraconazole amorphous solid dispersion tablets: formulation and compaction process optimization using Quality by Design principles and tools

    Papers - 07/11/2022 - by Hetvi Triboandas, Kendal Pitt, Mariana Bezerra, Delphine Ach-Hubert, Walkiria Schlindwein
    BCS Class II drugs, exemplified by itraconazole (ITZ), are characterized by poor solubility (1–4 ng/mL), necessitating solubility enhancement. Consequently, amorphous solid dispersions (ASDs) of ITZ and Kollidon® VA64 (KOL) were …
    Surface Characterization as a Tool for Identifying the Factors Affecting the Dissolution Rate of Amorphous Solid Dispersion Tablets

    Surface characterization as a tool for identifying the factors affecting the dissolution rate of amorphous solid dispersion tablets

    Papers - 17/10/2022 - by Dongyue Yu, Frederick Fiddler, Ahmed Ibrahim, Raymond Sanedrin, Heidi Tremblay, Stephen W. Hoag
    The amorphous solid dispersion (ASD) is a widely adopted strategy for improving the dissolution of drugs with poor aqueous solubility. However, the selection of an appropriate polymer and drug loading …
    Development of a multiparticulate drug delivery system for in situ amorphisation

    Development of a multiparticulate drug delivery system for in situ amorphisation

    Papers - 01/10/2022 - by Tobias Palle Holm, Marcel Kokott, Matthias Manne Knopp, Ben J. Boyd, Ragna Berthelsen, Julian Quodbach, Korbinian Löbmann
    In this study, the application of multiparticulate drug delivery systems (MDDS) was explored for tablets designed to amorphize supersaturated granular amorphous solid dispersions (ASDs) in situ—specifically, achieving amorphization through microwave …
    Development of an amorphous based sustained release system for apremilast a selective phosphodiesterase 4 (PDE4) inhibitor

    Development of an amorphous based sustained release system for apremilast a selective phosphodiesterase 4 (PDE4) inhibitor

    Papers - 05/03/2022 - by Qiangnan Zhang, Thomas Durig, Benjamin Blass, Reza Fassihi
    Apremilast, a selective PDE4 inhibitor approved for various inflammatory disorders, is categorized as a BCS-IV drug and exists in seven polymorphic forms. This study outlines the creation of a sustained-release …